Loading
HKSEHealthcareBiotechnology
Latest quote
HK$4.30
+HK$0.10 · +2.38%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
Latest quote
HK$4.30
+HK$0.10 · +2.38%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52-week range
Current HK$4.30
Historical prices · Market data may be delayed.
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52-week range
Current HK$4.30
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (HKD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 37.12M HKD | 77.92M HKD | 73.75M HKD | 37.38M HKD | 106.74M HKD |
| Cost of goods sold | 2.9M HKD | 15.43M HKD | 21.93M HKD | 10.18M HKD | 6.26M HKD |
| Gross profit | 34.22M HKD | 62.49M HKD | 51.83M HKD | 27.2M HKD | 100.48M HKD |
| Research and development | 92.33M HKD | 123.71M HKD | 140.05M HKD | 70.12M HKD | 139.78M HKD |
| Selling, general, and administrative | 42.54M HKD | 44.5M HKD | 154.17M HKD | 116.37M HKD | 402.18M HKD |
| Operating expenses | 183.68M HKD | 218.02M HKD | 293.09M HKD | 255.14M HKD | 511.93M HKD |
| Interest income | 5.1M HKD | 5.17M HKD | 14.54M HKD | 3.81M HKD | — |
| Interest expense | 102.82K HKD | 119.25K HKD | 63.09K HKD | 80.86K HKD | — |
| Depreciation and amortization | 11.52M HKD | 10.63M HKD | 11.76M HKD | 11.96M HKD | 11.55M HKD |
| Operating income | −151.39M HKD | −184.38M HKD | −241.26M HKD | −227.94M HKD | −411.45M HKD |
| Net income | −142.54M HKD | −155.89M HKD | −209.9M HKD | −182.81M HKD | −417.79M HKD |
Company facts updated Sep 14, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
